Complement-mediated enhancement of SARS-CoV-2 antibody neutralisation potency in vaccinated individuals

Jack Mellors (), Raman Dhaliwal, Stephanie Longet, Tom Tipton, Eleanor Barnes, Susanna J. Dunachie, Paul Klenerman, Julian Hiscox and Miles Carroll ()
Additional contact information
Jack Mellors: University of Oxford
Raman Dhaliwal: University of Oxford
Stephanie Longet: Inserm
Tom Tipton: University of Oxford
Eleanor Barnes: Oxford University Hospitals NHS Foundation Trust
Susanna J. Dunachie: Oxford University Hospitals NHS Foundation Trust
Paul Klenerman: Oxford University Hospitals NHS Foundation Trust
Julian Hiscox: University of Liverpool
Miles Carroll: University of Oxford

Nature Communications, 2025, vol. 16, issue 1, 1-15

Abstract: Abstract With the continued emergence of SARS-CoV-2 variants and concerns of waning immunity, there is a need for better defined correlates of protection to aid future vaccine and therapeutic developments. Whilst neutralising antibody titres are associated with protection, these are typically determined in the absence of the complement system, which has the potential to enhance neutralisation titres and strengthen correlates with protection in vivo. Here we show that replenishment of the complement system in neutralisation assays can significantly enhance neutralisation titres, with up to an ~83-fold increase in neutralisation of the BA.1.1.529 strain using cross-reactive sera from vaccination against the ancestral strain. The magnitude of enhancement significantly varies between individuals, viral strains (wild-type/VIC01 and Omicron/BA.1), and cell lines (Vero E6 and Calu-3), and is abrogated following heat-inactivation of the complement source. Utilising ACE2 competition assays, we show that the mechanism of action is partially mediated by reducing ACE2-spike interactions. Through the addition of compstatin (a C3 inhibitor) to live virus neutralisation assays, the complement protein C3 is shown to be required for maximum efficiency. These findings further our understanding of SARS-CoV-2 immunity and neutralisation, with implications for protection against emerging variants and assessing future vaccine and therapeutic developments.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-57947-8 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-57947-8

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-57947-8

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().